KR102250737B9 - 약물 전달과 내재화 효율이 강화된 약물복합체 - Google Patents

약물 전달과 내재화 효율이 강화된 약물복합체

Info

Publication number
KR102250737B9
KR102250737B9 KR1020200065959A KR20200065959A KR102250737B9 KR 102250737 B9 KR102250737 B9 KR 102250737B9 KR 1020200065959 A KR1020200065959 A KR 1020200065959A KR 20200065959 A KR20200065959 A KR 20200065959A KR 102250737 B9 KR102250737 B9 KR 102250737B9
Authority
KR
South Korea
Prior art keywords
drug
enhanced
complex
internalization efficiency
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020200065959A
Other languages
English (en)
Other versions
KR102250737B1 (ko
Inventor
이병철
윤혜원
최지영
정재호
송인호
김상은
Original Assignee
주식회사 비아이케이테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 비아이케이테라퓨틱스 filed Critical 주식회사 비아이케이테라퓨틱스
Priority to KR1020200065959A priority Critical patent/KR102250737B1/ko
Priority to KR1020210057705A priority patent/KR102362265B1/ko
Application granted granted Critical
Publication of KR102250737B1 publication Critical patent/KR102250737B1/ko
Priority to CN202180043422.5A priority patent/CN115702007A/zh
Priority to PCT/IB2021/054774 priority patent/WO2021245539A1/ko
Priority to AU2021284541A priority patent/AU2021284541B2/en
Priority to JP2022574209A priority patent/JP7646705B2/ja
Priority to CA3180590A priority patent/CA3180590A1/en
Priority to US17/928,879 priority patent/US20230226201A1/en
Priority to BR112022024287A priority patent/BR112022024287A2/pt
Priority to EP21818271.5A priority patent/EP4159242A4/en
Priority to KR1020220015688A priority patent/KR102443219B1/ko
Publication of KR102250737B9 publication Critical patent/KR102250737B9/ko
Priority to JP2024227935A priority patent/JP2025066706A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
KR1020200065959A 2020-06-01 2020-06-01 약물 전달과 내재화 효율이 강화된 약물복합체 Active KR102250737B1 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020200065959A KR102250737B1 (ko) 2020-06-01 2020-06-01 약물 전달과 내재화 효율이 강화된 약물복합체
KR1020210057705A KR102362265B1 (ko) 2020-06-01 2021-05-04 약물 전달과 내재화 효율이 강화된 약물복합체
EP21818271.5A EP4159242A4 (en) 2020-06-01 2021-06-01 DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICACY
JP2022574209A JP7646705B2 (ja) 2020-06-01 2021-06-01 薬物伝達と内在化効率が強化された薬物複合体
PCT/IB2021/054774 WO2021245539A1 (ko) 2020-06-01 2021-06-01 약물 전달과 내재화 효율이 강화된 약물복합체
AU2021284541A AU2021284541B2 (en) 2020-06-01 2021-06-01 Drug conjugate having enhanced drug delivery and internalization efficiency
CN202180043422.5A CN115702007A (zh) 2020-06-01 2021-06-01 具有提高的药物递送和内化效率的药物偶联物
CA3180590A CA3180590A1 (en) 2020-06-01 2021-06-01 Drug conjugate having enhanced drug delivery and internalization efficiency
US17/928,879 US20230226201A1 (en) 2020-06-01 2021-06-01 Drug conjugate having enhanced drug delivery and internalization efficiency
BR112022024287A BR112022024287A2 (pt) 2020-06-01 2021-06-01 Conjugado de medicamento com eficiência melhorada de distribuição de medicamento e internalização
KR1020220015688A KR102443219B1 (ko) 2020-06-01 2022-02-07 약물 전달과 내재화 효율이 강화된 약물복합체
JP2024227935A JP2025066706A (ja) 2020-06-01 2024-12-24 薬物伝達と内在化効率が強化された薬物複合体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200065959A KR102250737B1 (ko) 2020-06-01 2020-06-01 약물 전달과 내재화 효율이 강화된 약물복합체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210057705A Division KR102362265B1 (ko) 2020-06-01 2021-05-04 약물 전달과 내재화 효율이 강화된 약물복합체

Publications (2)

Publication Number Publication Date
KR102250737B1 KR102250737B1 (ko) 2021-05-11
KR102250737B9 true KR102250737B9 (ko) 2022-11-14

Family

ID=75914703

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020200065959A Active KR102250737B1 (ko) 2020-06-01 2020-06-01 약물 전달과 내재화 효율이 강화된 약물복합체
KR1020210057705A Active KR102362265B1 (ko) 2020-06-01 2021-05-04 약물 전달과 내재화 효율이 강화된 약물복합체
KR1020220015688A Active KR102443219B1 (ko) 2020-06-01 2022-02-07 약물 전달과 내재화 효율이 강화된 약물복합체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020210057705A Active KR102362265B1 (ko) 2020-06-01 2021-05-04 약물 전달과 내재화 효율이 강화된 약물복합체
KR1020220015688A Active KR102443219B1 (ko) 2020-06-01 2022-02-07 약물 전달과 내재화 효율이 강화된 약물복합체

Country Status (9)

Country Link
US (1) US20230226201A1 (ko)
EP (1) EP4159242A4 (ko)
JP (2) JP7646705B2 (ko)
KR (3) KR102250737B1 (ko)
CN (1) CN115702007A (ko)
AU (1) AU2021284541B2 (ko)
BR (1) BR112022024287A2 (ko)
CA (1) CA3180590A1 (ko)
WO (1) WO2021245539A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102250737B1 (ko) * 2020-06-01 2021-05-11 주식회사 비아이케이테라퓨틱스 약물 전달과 내재화 효율이 강화된 약물복합체
CN115304516B (zh) * 2022-07-12 2024-04-30 四川大学 具有非常规发色团的化合物及其制备和应用
CN115590979B (zh) * 2022-10-13 2025-06-13 清华大学 超分子复合物及其制备方法和应用
CN117959457A (zh) * 2022-10-26 2024-05-03 深圳先进技术研究院 一种用作靶蛋白降解剂的双功能化合物及其在靶蛋白溶酶体降解中的应用
CN115590975A (zh) * 2022-11-15 2023-01-13 无锡福祈制药有限公司（Cn） 丝裂霉素-rgd肽偶联物及其制备方法
CN120265331A (zh) 2023-07-31 2025-07-04 美国锔责任有限公司 [177Lu]镥-PSMA I&T组合物及其剂量测定、试剂盒、制备方法和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009027625A1 (de) 2009-07-10 2011-01-13 Robert Bosch Gmbh Elektrische Schaltung zur Übertragung von Signalen zwischen zwei Mastern und einem oder mehreren Slaves
KR101383655B1 (ko) * 2010-05-24 2014-04-10 주식회사 바이오이미징코리아 트리카르보닐 테크네슘-99ｍ 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물
AU2015242213A1 (en) * 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
EP3613792B1 (en) 2017-04-21 2021-02-24 Bright Gene Bio-Medical Technology Co., Ltd. Multi-arm targeted anti-cancer conjugate
KR20200064059A (ko) 2017-10-05 2020-06-05 소니 주식회사 프로그램가능한 수지상 약물
KR102250737B1 (ko) * 2020-06-01 2021-05-11 주식회사 비아이케이테라퓨틱스 약물 전달과 내재화 효율이 강화된 약물복합체

Also Published As

Publication number Publication date
KR20210148895A (ko) 2021-12-08
WO2021245539A9 (ko) 2022-03-17
KR102443219B1 (ko) 2022-09-14
JP2023534377A (ja) 2023-08-09
CN115702007A (zh) 2023-02-14
KR102362265B1 (ko) 2022-02-14
AU2021284541B2 (en) 2025-03-06
CA3180590A1 (en) 2021-12-09
EP4159242A4 (en) 2025-01-15
JP2025066706A (ja) 2025-04-23
WO2021245539A1 (ko) 2021-12-09
JP7646705B2 (ja) 2025-03-17
US20230226201A1 (en) 2023-07-20
KR102250737B1 (ko) 2021-05-11
KR20220024279A (ko) 2022-03-03
EP4159242A1 (en) 2023-04-05
AU2021284541A1 (en) 2023-02-09
BR112022024287A2 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
KR102250737B9 (ko) 약물 전달과 내재화 효율이 강화된 약물복합체
ZA202000480B (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability
IL289217A (en) Polyoxazoline-drug conjugates with novel pharmacokinetic properties
IL290698B (en) Maytansinoid derivatives with self–immolative peptide linkers and conjugates thereof
DK3922279T3 (da) Præparater til lægemiddelafgivelse og anvendelse heraf
CL2011001141S1 (es) Inhalador de medicamentos de cuerpo cilindrico y manto curvo convexo; en la porcion lateral hay cuatro sobresalientes y en la porcion lateral izquierda cinco sobresalientes; el manto del cuerpo tiene un elemento trunco conico horizontal de manto curvo concavo y seccion eliptica que tiene centrado en su base un elemento circular.
EP2983659A4 (en) ACTIVE DERIVATIVE POLYMER AND USES THEREOF
PL3334462T3 (pl) Kowalencyjne linkery w koniugatach przeciwciało-lek oraz sposoby ich wytwarzania i zastosowania
IL285577A (en) Medication delivery systems and methods
EP3928813C0 (en) PORTABLE DRUG DELIVERY DEVICE
EP3402548C0 (en) OCCLUSION RESOLUTION IN DRUG DELIVERY DEVICES, SYSTEMS, AND METHODS
IL294590A (en) Drug transfer device
HUE054587T2 (hu) In vivo gyógyszerbejuttató eszközök
HRP20181882T1 (hr) Peptidi i konjugat peptid-aktivni sastojak za ciljanje bubrega lijekom
EP4203886A4 (en) DRUG DOSAGE SYSTEMS AND METHODS
EP3908251C0 (en) COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL PRODUCTS AND USES THEREOF
EP4251650A4 (en) Novel conjugate molecules targeting cd39 and tgfbeta
EP4308205C0 (en) DRUG DELIVERY DEVICE
SI3710485T1 (sl) Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe
EP3793446A4 (en) ULTRASOUND-MEDIATED GENE AND DRUG RELEASE
PL4208227T3 (pl) Urządzenia do podawania leku z głowicą do wielokrotnego dawkowania
IL275380A (en) Surfactant peptide nanostructures and uses in drug delivery
EP4380647A4 (en) MEDICATION DELIVERY PUMP
EP2854778A4 (en) DELAYED RELEASE OF MOLECULES USING PEPTIDTENSIDES AND USES THEREOF
EP4260839A4 (en) MEDICATION DISTRIBUTOR

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-5-5-R10-R15-oth-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-5-5-R10-R16-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20221114

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1022507370000

Gazette reference publication date: 20210511

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000